Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R01 Clinical Trial Not Allowed)
ID: 349671Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $350K

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/349671

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-23-254.html
Timeline
    Description

    The National Institutes of Health (NIH) is offering a funding opportunity titled "Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes" (NOFO Number PAR-23-254). This initiative aims to support applications that propose secondary data analysis and integration of existing datasets to investigate cancer risk factors, treatment responses, survival rates, and other related outcomes, utilizing innovative analysis methods across various data types, including clinical, genomic, behavioral, and environmental datasets. The program allows for up to $350,000 in direct costs annually, with a maximum project period of five years, and applications are due by specific dates starting from October 5, 2023, with subsequent cycles extending into 2027. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov, and additional details can be found at the provided link: https://grants.nih.gov/grants/guide/pa-files/PAR-23-254.html.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-23-254-Full-Announcement.html
    PAR-23-254.html
    The National Cancer Institute (NCI) is inviting applications for the research funding opportunity titled "Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes" (NOFO Number PAR-23-254). This program aims to fund secondary data analysis and integration of various existing datasets to explore cancer risk factors, treatment responses, survival rates, and other related outcomes. Applicants are encouraged to apply innovative analysis methods utilizing a range of data types, including clinical, genomic, behavioral, and environmental datasets. The funding opportunity allows for up to $350,000 direct costs annually, with a maximum project period of five years. Applications are due by specific dates, commencing from October 5, 2023, with subsequent cycles for new submissions stretching into 2027. Notably, this initiative does not permit new clinical trials or data collection beyond limited validation efforts. The document elaborates on eligibility requirements, application processes, and review criteria, emphasizing compliance with data management and sharing guidelines established by NIH policies. This initiative reflects NCI’s commitment to leveraging existing data to further cancer research efficiency and effectiveness, addressing significant knowledge gaps in the field of oncology.
    Similar Opportunities
    Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R01 Clinical Trial Not Allowed)." This initiative aims to support applications that propose secondary data analysis and integration of existing datasets to better understand cancer risk factors and related outcomes, including survival and treatment responses. The program emphasizes the importance of leveraging clinical, genomic, lifestyle, and environmental data to address significant scientific questions in cancer research. Interested applicants can apply for grants with a maximum budget of $350,000 per year, with a project duration of up to five years. The application deadline is September 7, 2026, and further details can be obtained by contacting NIH Grants Information at grantsinfo@nih.gov or visiting the official announcement at https://grants.nih.gov/grants/guide/pa-files/PAR-25-095.html.
    Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R21 Clinical Trials Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), is offering a funding opportunity for secondary analysis and integration of existing datasets to elucidate cancer risk and related outcomes. This initiative encourages innovative research that leverages existing clinical, genomic, and epidemiological data to address critical questions in cancer control, with a focus on risk prediction, survival, and treatment responses. Eligible applicants include a wide range of organizations such as higher education institutions, nonprofits, and foreign entities, with a budget cap of $275,000 over a two-year period. Applications are due by September 7, 2026, and interested parties can find more information and contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-23-255.html.
    Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R21 Clinical Trials Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R21 Clinical Trials Not Allowed)." This initiative encourages applications that propose innovative secondary data analyses and integration of existing datasets to address significant scientific questions related to cancer risk, prevention, and treatment outcomes. The program aims to leverage diverse data sources, including clinical, environmental, and genomic datasets, to enhance understanding of cancer and improve public health strategies. Eligible applicants include a wide range of organizations, such as higher education institutions, nonprofit organizations, and tribal governments, with a maximum funding amount of $200,000 and a project duration of up to two years. Interested parties can find more information and application details at the NIH grants website, with the submission deadline set for September 7, 2026.
    Innovative Approaches to Studying Cancer Communication in the New Information Ecosystem (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Innovative Approaches to Studying Cancer Communication in the New Information Ecosystem," aimed at supporting exploratory research projects in cancer communication. This initiative focuses on three key areas: developing new cancer communication surveillance strategies, creating rapid intervention methods, and establishing multilevel communication models to enhance cancer prevention and control efforts. The NIH emphasizes the importance of utilizing contemporary methodologies, such as social media analysis and artificial intelligence, to address misinformation and improve health literacy in cancer care. Eligible applicants can receive funding of up to $275,000 for a maximum duration of two years, with applications due by September 7, 2025. For further inquiries, interested parties can contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov or refer to the detailed announcement at http://grants.nih.gov/grants/guide/pa-files/PAR-22-165.html.
    Cancer Epidemiology Cohorts: Building the Next Generation of Research Cohorts (U01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the funding opportunity titled "Cancer Epidemiology Cohorts: Building the Next Generation of Research Cohorts," aimed at establishing new population-based cancer epidemiology cohorts to address critical gaps in cancer etiology and survivorship. This initiative emphasizes the importance of engaging diverse and understudied populations, focusing on innovative recruitment strategies, community partnerships, and novel data collection methods over a five-year project period. The funding will be provided through a cooperative agreement, which requires substantial involvement from NIH, with applications due by March 1, 2025, and an anticipated earliest start date of February 28, 2025. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov, and additional details can be found at the provided link: https://grants.nih.gov/grants/guide/pa-files/PAR-25-186.html.
    Impacts of climate change across the cancer control continuum (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), has announced a funding opportunity titled "Impacts of Climate Change Across the Cancer Control Continuum," aimed at supporting innovative research on the effects of climate change on cancer risks, control, and survivorship. This R21 Exploratory/Developmental Research Grant encourages multidisciplinary studies that explore the relationship between climate change and cancer-related health disparities, necessitating collaboration with climate change experts. The grant offers a budget cap of $275,000 for a two-year project period, with applications opening on January 16, 2025, and closing on May 7, 2026. Interested applicants can find more information and application instructions at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Research Opportunities in Established Cancer Epidemiology Cohort Studies (U01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), is offering a funding opportunity for research in established cancer epidemiology cohort studies under the U01 cooperative agreement mechanism. This initiative aims to support hypothesis-driven research utilizing data from cohorts that have achieved their initial recruitment goals, focusing on cohort maintenance, continuous follow-up, and resource sharing while addressing significant cancer control questions. The program encourages applications that leverage existing cohort data to explore understudied populations and cancer exposures, with no budget limits reflecting project needs and a maximum project duration of five years. Interested applicants must register with Grants.gov and adhere to NIH data-sharing policies, with the application deadline set for February 28, 2025. For further inquiries, applicants can contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov or visit the opportunity's webpage at http://grants.nih.gov/grants/guide/pa-files/PAR-22-162.html.
    Clinical Characterization of Cancer Therapy-induced Adverse Sequelae and Mechanism-based Interventional Strategies (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), has announced a funding opportunity titled "Clinical Characterization of Cancer Therapy-induced Adverse Sequelae and Mechanism-based Interventional Strategies." This initiative aims to support innovative research projects that investigate the adverse effects of cancer therapies, particularly those that lead to chronic comorbidities or delayed sequelae, with a focus on understanding the underlying mechanisms and developing therapeutic strategies to mitigate these long-term issues. The funding is open to a diverse range of applicants, including educational institutions, non-profits, and foreign organizations, and requires a Plan for Enhancing Diverse Perspectives (PEDP) as part of the application. Applications must be submitted electronically by January 5, 2025, with awards contingent on available funding and merit assessed through NIH's peer-review process. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), is offering a funding opportunity titled "NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional)" aimed at supporting innovative preclinical and early-phase clinical research in cancer diagnosis, treatment, and prevention. This grant, with a funding ceiling of $275,000 over two years, encourages exploratory studies that may involve significant risk but have the potential to lead to breakthroughs in cancer research, particularly for underserved populations. Applications will be evaluated based on their significance, innovation, and rigor, with key deadlines for submission set for January 2025. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.
    Basic Research in Cancer Health Disparities (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a Notice of Funding Opportunity (NOFO) for the Basic Research in Cancer Health Disparities grant, aimed at supporting innovative research into the biological and genetic causes of cancer health disparities among diverse racial and ethnic populations. This grant encourages applications from a wide range of eligible applicants, including higher education institutions, nonprofits, and organizations serving underrepresented groups, with a focus on mechanistic studies, new methodologies, and the use of biospecimens to uncover cancer risk factors and develop prevention strategies. The application process opens on January 5, 2025, with the first submission deadline on February 5, 2025, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries. More details can be found at the provided link: https://grants.nih.gov/grants/guide/pa-files/PAR-25-243.html.